Immunotherapy regimes dependent on ApoE status

Patent metadata

Field	Value
Publication number	US-9644025-B2
Application number	US-73839608-A
Country	US
Kind code	B2
Filing date	Oct 17, 2008
Priority date	Oct 17, 2007
Publication date	May 9, 2017
Grant date	May 9, 2017

Abstract

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

First claim

What is claimed is:

1. A method of treating a disease characterized by Aβ deposits in the brain of patient comprising intravenously or subcutaneously administering an effective regime of a humanized antibody to a population of patients suffering from the disease; wherein the humanized antibody comprises a mature light chain variable region sequence of SEQ ID NO:2 and a mature heavy chain variable region sequence of SEQ ID NO:3, and a human heavy chain constant region of IgG1 isotype with L234A, L235A, and G237A mutations, wherein positions are numbered by the EU numbering system, and thereby treating the disease in the patients, wherein the regime administered to different patients in the population does not depend on the number of ApoE4 alleles present in a patient.

2. The method of claim 1 , wherein the dose is 0.15-1 mg/kg.

3. The method of claim 1 , wherein the dose is 0.15-2 mg/kg.

4. The method of claim 1 , wherein the dosage is 10 mg/kg.

5. The method of claim 1 , further comprising monitoring the patient by MRI for vasogenic edema.

6. The method of claim 1 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.

7. The method of claim 2 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.

8. The method of claim 3 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.

9. The method of claim 5 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.

10. The method of claim 1 , wherein the disease is Alzheimer's disease.

11. The method of claim 6 , wherein the disease is Alzheimer's disease.

12. The method of claim 7 , wherein the disease is Alzheimer's disease.

13. The method of claim 8 , wherein the disease is Alzheimer's disease.

14. The method of claim 9 , wherein the disease is Alzheimer's disease.

15. A method of reducing the risk, lessening the severity or delaying the outset of a disease characterized by Aβ deposits in the brain of patient comprising administering an effective regime of a humanized antibody to a population of patients susceptible to the disease; wherein the humanized antibody comprises a mature light chain variable region sequence of SEQ ID NO:2 and a mature heavy chain variable region sequence of SEQ ID NO:3, and a human heavy chain constant of IgG1 isotype with L234A, L235A, and G237A mutations, wherein positions are numbered by the EU numbering system, thereby reducing the risk, lessening the severity or delaying the outset of the disease in the patients, wherein the regime administered to different patients in the population does not depend on the number of ApoE4 alleles present in a patient.

16. The method of claim 15 , wherein the dose is 0.15-1 mg/kg.

17. The method of claim 15 , wherein the dose is 0.15-2 mg/kg.

18. The method of claim 15 , further comprising monitoring the patient by MRI for vasogenic edema.

19. The method of claim 15 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.

20. The method of claim 16 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.

21. The method of claim 17 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.

22. The method of claim 18 , wherein the antibody is an L234A, L235A, G237A variant of bapineuzumab.

23. The method of claim 15 , wherein the disease is Alzheimer's disease.

24. The method of claim 19 , wherein the disease is Alzheimer's disease.

25. The method of claim 20 , wherein the disease is Alzheimer's disease.

26. The method of claim 21 , wherein the disease is Alzheimer's disease.

27. The method of claim 22 , wherein the disease is Alzheimer's disease.

Assignees

• Black Ronald
• Ekman Lars
• Lieberburg Ivan
• Grundman Michael
• Callaway James
• Gregg Keith M
• Jacobsen Jack Steven
• Gill Davinder
• Tchistiakova Lioudmila
• Widom Angela
• Wyeth Llc
• Janssen Sciences Ireland Uc

Inventors

• Black Ronald
• Ekman Lars
• Lieberburg Ivan
• Grundman Michael
• Callaway James
• Gregg Keith M
• Jacobsen Jack Steven
• Gill Davinder
• Tchistiakova Lioudmila
• Widom Angela

Classifications

• A61P7/10

  Antioedematous agents; Diuretics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title